186 related articles for article (PubMed ID: 7651442)
1. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
2. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
[No Abstract] [Full Text] [Related]
3. P450 enzymes and Parkinson's disease: the story so far.
Riedl AG; Watts PM; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):212-20. PubMed ID: 9539332
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
[TBL] [Abstract][Full Text] [Related]
5. Association between the oxidative polymorphism and early onset of Parkinson's disease.
Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
[TBL] [Abstract][Full Text] [Related]
6. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
Kurth MC; Kurth JH
Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
[TBL] [Abstract][Full Text] [Related]
7. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease.
Saitoh T; Xia Y; Chen X; Masliah E; Galasko D; Shults C; Thal LJ; Hansen LA; Katzman R
Ann Neurol; 1995 Jan; 37(1):110-2. PubMed ID: 7818242
[TBL] [Abstract][Full Text] [Related]
8. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
12. Lack association between schizophrenia and the CYP2D6 gene polymorphisms.
Pirmohamed M; Wild MJ; Kitteringham NR; O'Brien K; Buchan IE; Back DJ; Park BK
Am J Med Genet; 1996 Apr; 67(2):236-7. PubMed ID: 8723057
[No Abstract] [Full Text] [Related]
13. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
[TBL] [Abstract][Full Text] [Related]
14. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
[TBL] [Abstract][Full Text] [Related]
15. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
16. [Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson's disease].
Wang J; Liu Z; Chen B
Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):585-7. PubMed ID: 11798822
[TBL] [Abstract][Full Text] [Related]
17. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease].
Tao E; Liu Z; Chen B; Pan X; Shao M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873
[TBL] [Abstract][Full Text] [Related]
18. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
[TBL] [Abstract][Full Text] [Related]
19. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
